BioVie targets Parkinson's at its source with lead drug bezisterim

Core Viewpoint - BioVie Inc is advancing a new hypothesis regarding Parkinson's disease, suggesting that inflammation and insulin resistance in the brain may play a significant role alongside dopamine loss, which has traditionally been the focus of treatment [2][3][4]. Group 1: Disease Understanding - Parkinson's disease affects approximately one million people in the U.S., with prevalence expected to rise due to aging populations [3]. - The traditional treatment approach has remained largely unchanged for over 50 years, primarily focusing on dopamine replacement [3]. - BioVie proposes that insulin resistance may be central to neurodegeneration and neuronal dysfunction, impacting glucose metabolism and dopamine production [4][5][6]. Group 2: Limitations of Current Treatments - Levodopa, while effective in restoring muscle control, has significant limitations including a short half-life requiring multiple daily doses, leading to "off" periods where symptoms return [7][8]. - Over time, the effectiveness of levodopa diminishes, necessitating higher doses that can result in levodopa-induced dyskinesia, causing involuntary movements [8][9]. Group 3: New Drug Candidate - Bezisterim - Bezisterim is an oral small molecule designed to cross the blood-brain barrier, targeting inflammation and improving insulin sensitivity without immune suppression [10][11]. - Early Phase 2 studies indicated that bezisterim, when combined with levodopa, improved motor control and "morning on" function compared to levodopa alone [11][12]. Group 4: Clinical Trials and Future Directions - BioVie has completed enrollment in the 60-patient Phase 2 SUNRISE-PD trial, focusing on patients diagnosed within the past four years who have not yet started levodopa treatment [13][14]. - The trial aims to assess both motor and non-motor symptoms using the Unified Parkinson's Disease Rating Scale (UPDRS) and incorporates biomarker analysis for future development [13][15]. - Topline results from the SUNRISE-PD trial are expected in the first half of 2026, which could significantly impact Parkinson's treatment if successful [16][17]. Group 5: Long-term Vision - If successful, bezisterim could be the first drug to demonstrate the ability to delay the progression of Parkinson's disease, potentially becoming a first-line therapy introduced early in treatment [18][19]. - The drug's administration as an oral capsule taken twice daily, or potentially once daily, could simplify treatment regimens compared to the frequent dosing required for levodopa [20].